Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RESMED INC Director's Dealing 2022

Oct 18, 2022

30071_dirs_2022-10-17_20c1c259-42ed-45f1-acb5-6457c98a7e87.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2022-10-14

Reporting Person: Douglas Robert Andrew (President and COO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-10-14 ResMed Common Stock M 1145 $58.24 Acquired 29553 Direct
2022-10-14 ResMed Common Stock M 16888 $58.24 Acquired 46441 Direct
2022-10-14 ResMed Common Stock S 11355 $215.0857 Disposed 35086 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-10-14 ResMed Common Stock Options $58.24 M 1145 Disposed 2022-11-19 ResMed Common Stock (1145) Direct
2022-10-14 ResMed Common Stock Options $58.24 M 16888 Disposed 2022-11-19 ResMed Common Stock (16888) Direct

Holdings (Non-Derivative)

Security Shares Ownership
ResMed Common Stock 227708 Indirect

Footnotes

F1: The transaction was conducted under a Rule 10b5-1 plan.

F2: This transaction was executed in multiple trades at prices ranging from $213.62 to $217.36. The price reported above reflects the weighted average sale price.

F3: Represents date options first became exercisable. Options vest 1/3 per year.